The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome
Table 2
Characteristics of the first 10 patients, including changes in the ventilator requirements and PaO2/FiO2 ratio (ventilatory and clinical features of critically ill patients with COVID-19 infection and ARDS treated with dornase alfa).
Patient I
Patient II
Patient III
Patient IV
Patient V
Patient VI
Patient VII
Patient VIII
Patient IX
Patient X
Age
72
68
48
62
68
42
48
55
79
35
Sex
M
M
F
M
F
M
M
M
M
M
Comorbidities
Renal transplant, type II DM, prior history of malignancy
—
PAF, type II DM
—
HTN
—
CAD with prior STEMI
—
Pulmonary fibrosis
CM
COVID+ by RT-PCR
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
No
Remdesivir use
Yes
Yes
Yes
No
No
No
No
No
No
No
Respiratory support (before) Pressure (cmH2O) Volume (mL)
PCV: 28/12
PRVC TV: 450 mL VR: 32 bpm PEEP: 14
PRVC TV: 450 mL VR: 30 bpm PEEP: 16
HFNC
HFNC
BiPap
PRVC TV: 450 mL VR: 22 bpm PEEP: 12
BiPap
PCV 22/12
PRVC TV: 450 mL VR: 22 bpm PEEP: 10
Respiratory support (after) Pressure (cmH2O) Volume (mL)
